Buy Zydus Lifesciences; target of Rs 1400: Choice Institutional Equities

Moneycontrol • 1 day ago

Original source

Key Investment Pillars

  • Zydus Lifesciences' strong pipeline, increasingly focused on specialty and complex products, is expected to drive revenue growth of 17.2% CAGR in FY26-29E.
  • The company's India formulations business is projected to sustain mid-teens growth, outperforming the domestic pharmaceutical market by 200-400 bps.
  • The US business strategy is shifting towards a diversified specialty and biologics portfolio, with key launches including Saroglitazar, Palbociclib, and Pembrolizumab.
  • International markets are expected to remain a key growth engine, driven by a therapy-led strategy in emerging markets and continued portfolio expansion in Europe.

Thesis Validation Checklist

  • Investors should watch for sustained double-digit revenue growth, driven by a richer mix of branded and differentiated products.
  • Margin growth is expected to outpace revenue growth over the medium term, driven by a higher branded mix, US specialty scale-up, and innovation-led growth.
  • Key launches, such as Saroglitazar and Palbociclib, are expected to contribute meaningfully to revenue growth.
  • The company's ability to maintain its strong pipeline and execute on its growth strategy will be crucial in validating the investment thesis.